Literature DB >> 817790

Clinical manifestations of multiple myeloma: relation to class and type M component.

W Pruzanski.   

Abstract

From analysis of serum samples and clinical data from 632 patients with multiple myeloma it was determined that IgG was the commonest class of myeloma and that this type seemed to be the most benign. IgD myeloma and lambda light-chain disease were the most aggressive types; patients with these types were usually younger at diagnosis and more commonly had azotemia, osteolytic lesions and Bence Jones proteinemia. The sexes were equally represented in all but IgD myeloma, in which males predominated. Prognosis was more favourable when the M component had kappa light chains.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 817790      PMCID: PMC1957069     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  11 in total

1.  Immunochemical classes of myelomatosis. Including data from a therapeutic trial conducted by a Medical Research Council working party.

Authors:  J R Hobbs
Journal:  Br J Haematol       Date:  1969-06       Impact factor: 6.998

2.  Serum viscosity and hyperviscosity syndrome in IgG multiple myeloma. Report on 10 patients and a review of the literature.

Authors:  W Pruzanski; J G Watt
Journal:  Ann Intern Med       Date:  1972-12       Impact factor: 25.391

3.  Multiple myeloma incidence in metropolitan Atlanta, Georgia: racial and seasonal variations.

Authors:  P McPhedran; C W Heath; J Garcia
Journal:  Blood       Date:  1972-06       Impact factor: 22.113

4.  Multiple myeloma in Olmsted County, Minnesota, 1945-1964.

Authors:  R A Kyle; F T Nobrega; L T Kurland
Journal:  Blood       Date:  1969-05       Impact factor: 22.113

Review 5.  The changing pattern of diseases associated with M components.

Authors:  W Pruzanski; M A Ogryzlo
Journal:  Med Clin North Am       Date:  1972-03       Impact factor: 5.456

6.  Pathologic conditions associated with plasma cell dyscrasias: a study of 806 cases.

Authors:  T Isobe; E F Osserman
Journal:  Ann N Y Acad Sci       Date:  1971-12-31       Impact factor: 5.691

7.  Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients.

Authors:  P P Carbone; L E Kellerhouse; E A Gehan
Journal:  Am J Med       Date:  1967-06       Impact factor: 4.965

8.  Treatment of plasma cell myeloma with cytotoxic agents.

Authors:  D E Bergsagel; W Pruzanski
Journal:  Arch Intern Med       Date:  1975-01

9.  Plasma cell myeloma with D-myeloma protein (IgD myeloma).

Authors:  J L Fahey; P P Carbone; D S Rowe; R Bachmann
Journal:  Am J Med       Date:  1968-09       Impact factor: 4.965

10.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

View more
  3 in total

1.  Multiple myeloma.

Authors:  R M Meyer
Journal:  Can Fam Physician       Date:  1985-06       Impact factor: 3.275

2.  IgG myeloma presenting as ulcerative colitis.

Authors:  M R Haeney; I N Ross; R A Thompson; P Asquith
Journal:  J Clin Pathol       Date:  1977-09       Impact factor: 3.411

3.  Immunoglobulin D myeloma: report of a case with unusual neurological complications.

Authors:  V Caggiano; S L Nielsen; F J Glassy; D F Dozier
Journal:  West J Med       Date:  1981-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.